C-C Chemokine Receptor Type 5 (CCR5) Antibody

Product specifications

Primary Antibodies

Target: C-C Chemokine Receptor Type 5 (CCR5)
Immunogen: abx652869 - Recombinant Chemokine C-C-Motif Receptor 5 (CCR5)

Rabbit

Human

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.

100 µl

200 µl

1 ml

Liquid

WB, IHC, IF/ICC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Shipped within 5-7 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

CCR5,CHEMR13,CC CKR5,CKR5,CD195,MIP-1 alpha receptor,chemokine (C-C motif) receptor 5 (gene/pseudogene),C-C motif chemokine receptor 5 (gene/pseudogene),CCR-5,CCCKR5,CMKBR5,IDDM22

Antibody anti-CCR5

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Descripción

C-C Chemokine Receptor Type 5 (CCR5) is a G-protein-coupled receptor expressed on the surface of macrophages, monocytes, T lymphocytes, and dendritic cells. CCR5 is a key player in immune surveillance and inflammatory responses, binding chemokines such as CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) to mediate the chemotaxis and activation of immune cells. Importantly, CCR5 serves as a co-receptor for HIV-1 entry into host cells, making it a critical target in HIV/AIDS treatment. Individuals with a genetic CCR5Δ32 deletion exhibit resistance to HIV-1 infection, highlighting its role in viral pathogenesis. In addition to HIV, CCR5 contributes to immune responses in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where excessive chemokine signaling drives inflammation and tissue damage. CCR5 is also implicated in cancer progression, facilitating the recruitment of immune suppressive cells and metastasis by enhancing tumor-immune interactions. Therapeutic interventions targeting CCR5 include CCR5 antagonists like maraviroc, approved for treating HIV-1, and emerging therapies for autoimmune diseases and cancers. Recent studies also link CCR5 to recovery from stroke and neuroinflammation, highlighting its diverse roles in immunity, infection, and disease progression. Continued research on CCR5 biology may expand its applications in antiviral therapy, immunotherapy, and inflammatory disease management.

Related Products

Human C-C Chemokine Receptor Type 5 (CCR5) Protein

Human Chemokine C-C-Motif Receptor 5 (CCR5) Protein is a recombinant Human protein expressed in E. coli.

Ver Producto